Also trades as: 0HI3.L (LSE) · $vol 0M
ARWR NASDAQ
Arrowhead Pharmaceuticals, Inc.
1W: +0.2%
1M: -9.8%
3M: -31.5%
YTD: -12.9%
1Y: +55.3%
3Y: +132.0%
5Y: -12.0%
$59.03
+0.05 (+0.08%)
Weekly Expected Move ±4.7%
$53
$55
$58
$61
$63
Credit Risk of going bust: higher than 52% of companies Debt: 9.4% of company value Bonds: $79.9M held by 47 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.78 (down 99%), Arrowhead Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $864.1M against a stock market value of $8.34B.
Distance to default 4.96 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $452.0M (short-term plus half of long-term), stock volatility 60.3%; Altman Z'' 1.13. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.78 (down 99%), Arrowhead Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $864.1M against a stock market value of $8.34B.
Distance to default 4.96 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $452.0M (short-term plus half of long-term), stock volatility 60.3%; Altman Z'' 1.13. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Ionis upgraded at BMO on Tryngolza adoption for severe hypertriglyceridemia
Arrowhead spikes after early-stage trial data for Alzheimer’s disease
Catalyst watch: Big bank earnings, CPI, and the Paris Auto Show
These healthcare stocks stand out with A+ growth grades
These ten healthcare stocks posted the biggest one-month losses
ARWR Stock On Track For Worst Day In Over A Year Despite Positive Early-Stage Data For Cholesterol Drug — Retail Dismisses ‘Sell The News’ Reaction - stocktwits.com
ARWR Stock On Track For Worst Day In Over A Year Despite Positive Early-Stage Data For Cholesterol Drug — Retail Dismisses ‘Sell The News’ Reaction
Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 8.93% on Sep 15: What Investors Need To Know - TradingKey
ARWR Looks 59.6% Overvalued on GF Value™ - GuruFocus
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
One experimental therapy silenced two genes at once. More results will follow at a medical congress. - Stock Titan
Goldman rebalances its long duration stock basket
California State Teachers Retirement System Buys 11,252,904 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Hsbc Holdings PLC Boosts Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026
ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 - Yahoo Finance
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Arrowhead Pharmaceuticals (ARWR) Stock Looks Cheap On Cash Flow Yet Fair On Sales - simplywall.st
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Benjamin Edwards Inc. Makes New $721,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress?
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress? - Yahoo Finance
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials
Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating?
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? - Yahoo Finance
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Flashes Bull Flag Breakout Setup with Top-Tier Technical Strength - ChartMill
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
EP Wealth Advisors LLC Purchases New Shares in Arrowhead Pharmaceuticals, Inc. $ARWR
Deutsche Bank AG Invests $12.16 Million in Arrowhead Pharmaceuticals, Inc. $ARWR
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress - simplywall.st
ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG
Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
California State Teachers Retirement System Has $9.05 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by Affinity Asset Advisors LLC
California Public Employees Retirement System Makes New Investment in Arrowhead Pharmaceuticals, Inc. $ARWR
Bank of New York Mellon Corp Acquires 72,296 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - stocktwits.com
Arrowhead (ARWR) Shares Surge Over 22% - GuruFocus
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR) - Seeking Alpha
Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
ARWR Jumps As REDEMPLO Win Fuels Bullish Targets - StocksToTrade
Arrowhead Pharmaceuticals (ARWR) Achieves Late-Stage Trial Succe - GuruFocus
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Yahoo Finance
Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (ARWR) Reports Positive Phase 3 Trial Results - GuruFocus
Arrowhead Pharmaceuticals stock jumps on Phase 3 trial results - Investing.com
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - stocktwits.com
Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run - Yahoo Finance
Arrowhead's Fiscal Q3 Results Get a Live Webcast Aug. 4 - Stock Titan
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
ARWR Rallies 7% This Week As Europe Edges Closer To Redemplo Approval Amid Analyst Optimism - Stocktwits
Arrowhead Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ARWR) - TradingView
Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In? - simplywall.st
Arrowhead Pharmaceuticals Gains as Investors Revisit Recent Bullish Coverage and Upcoming Pipeline Catalysts - Quiver Quantitative
7 Red Days In A Row: Arrowhead Pharmaceuticals Stock Is Down 18% - Trefis
Arrowhead Pharmaceuticals Stock 7-Day Losing Spree: Stock Falls 18% - Trefis
Arrowhead Pharmaceuticals Stock Slides 17% With A 6-Day Losing Spree - Trefis
6 Red Days In A Row: Arrowhead Pharmaceuticals Stock Is Down 17% - Trefis
5 Red Days In A Row: Arrowhead Pharmaceuticals Stock Is Down 17% - Trefis
Arrowhead Pharmaceuticals Stock In Shambles: Down 17% With 5-Day Losing Streak - Trefis
Arrowhead gains EU authorisation for Redemplo in evolving FCS market
Here Are Tuesday’s Best Wall Street Analyst Research Calls: Apple, Bloom Energy, Circle Internet Group, First Solar, Halliburton, IBM, Intuit, Newmont, SK hynix, and More
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
The Long Climb Back For Ionis Stock
Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 7.27% on Jul 10: What Signal Does It Send? - TradingKey
Price to book forward of Arrowhead Pharmaceuticals, Inc. – NASDAQ:ARWR - TradingView
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus
ARWR - Arrowhead Pharmaceuticals Inc Stock Price and Quote - Finviz
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026 - Yahoo Finance
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum
Insider Sale: Director at $ARWR Sells 2,970 Shares | ARWR Stock News - Quiver Quantitative
Arrowhead (ARWR) Q2 2026 Earnings Transcript
Arrowhead anticipates SHASTA-3/4 topline in Q3 while planning an SHTG sNDA before end of 2026
Arrowhead Pharmaceuticals GAAP EPS of -$0.93 beats by $0.19, revenue of $73.73M beats by $2.02M
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
Here are the major earnings after the close Thursday
This Littelfuse Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
B. Metzler seel. Sohn & Co. AG Takes $1.37 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR